Idera Pharmaceuticals Company Profile (NASDAQ:IDRA)

About Idera Pharmaceuticals

Idera Pharmaceuticals logoIdera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company's drug candidates include IMO-8400; IMO-2125/IMO-2055, and IMO-9200. The Company's TLR antagonist lead drug candidates are IMO-8400 and IMO-9200, which are both antagonists of TLR7, TLR8 and TLR9. Its TLR agonist lead drug candidates are IMO-2055 and IMO-2125, which are both agonists of TLR9.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: IDRA
  • CUSIP:
Key Metrics:
  • Previous Close: $2.31
  • 50 Day Moving Average: $2.14
  • 200 Day Moving Average: $1.80
  • 52-Week Range: $1.19 - $4.42
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.33
  • P/E Growth: 0.00
  • Market Cap: $310.73M
  • Outstanding Shares: 121,378,000
  • Beta: 2.78
Profitability:
  • Net Margins: -6,169.32%
  • Return on Equity: -64.09%
  • Return on Assets: -58.44%
Debt:
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 9.14%
  • Quick Ratio: 9.14%
Additional Links:
Companies Related to Idera Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Idera Pharmaceuticals (NASDAQ:IDRA) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.50 (153.91% upside)

Analysts' Ratings History for Idera Pharmaceuticals (NASDAQ:IDRA)
Show:
DateFirmActionRatingPrice TargetDetails
9/26/2016WedbushReiterated RatingOutperform$6.00View Rating Details
5/10/2016Cowen and CompanyReiterated RatingBuyView Rating Details
3/12/2016Piper Jaffray Cos.Reiterated RatingBuyView Rating Details
6/15/2015JPMorgan Chase & Co.Initiated CoverageOverweight$6.00View Rating Details
(Data available from 10/1/2014 forward)

Earnings

Earnings History for Idera Pharmaceuticals (NASDAQ:IDRA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/4/2016        
8/2/2016Q216($0.11)($0.11)ViewN/AView Earnings Details
5/9/2016Q1($0.11)($0.11)ViewListenView Earnings Details
3/10/2016Q4($0.11)($0.10)$20.00 millionViewN/AView Earnings Details
11/6/2015Q315($0.11)($0.10)ViewN/AView Earnings Details
8/6/2015Q215($0.11)($0.11)ViewN/AView Earnings Details
5/11/2015Q1($0.11)($0.12)$0.03 millionViewN/AView Earnings Details
3/12/2015Q414($0.11)($0.14)$0.03 millionViewN/AView Earnings Details
11/7/2014Q314($0.11)($0.11)ViewListenView Earnings Details
8/12/2014Q214($0.09)($0.10)ViewListenView Earnings Details
5/13/2014Q114($0.08)($0.12)ViewListenView Earnings Details
3/13/2014Q4($0.08)($0.10)ViewListenView Earnings Details
11/14/2013Q3($0.11)($0.11)$0.03 million$0.01 millionViewListenView Earnings Details
8/15/2013Q213($0.12)($0.15)ViewN/AView Earnings Details
5/15/2013Q113($0.19)($0.15)ViewN/AView Earnings Details
3/11/2013Q4 2012($0.24)ViewN/AView Earnings Details
11/12/2012Q312($0.17)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Idera Pharmaceuticals (NASDAQ:IDRA)
Current Year EPS Consensus Estimate: $-0.45 EPS
Next Year EPS Consensus Estimate: $-0.48 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.11)($0.10)($0.11)
Q2 20161($0.11)($0.11)($0.11)
Q3 20162($0.11)($0.09)($0.10)
Q4 20161($0.10)($0.10)($0.10)
Q1 20171($0.10)($0.10)($0.10)
Q2 20171($0.11)($0.11)($0.11)
Q3 20171($0.10)($0.10)($0.10)
Q4 20171($0.10)($0.10)($0.10)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Idera Pharmaceuticals (NASDAQ:IDRA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Idera Pharmaceuticals (NASDAQ:IDRA)
Insider Ownership Percentage: 29.50%
Institutional Ownership Percentage: 28.44%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/13/2016James A GeraghtyDirectorBuy10,000$1.34$13,400.00View SEC Filing  
5/12/2016Mark J CaseyVPBuy34,450$1.44$49,608.00View SEC Filing  
3/15/2016Vincent MilanoCEOBuy40,000$1.97$78,800.00View SEC Filing  
2/13/2015Julian BakerDirectorBuy5,333,333$3.75$19,999,998.75View SEC Filing  
12/16/2014Youssef El ZeinDirectorSell100,000$3.68$368,000.00View SEC Filing  
12/12/2014Vincent MilanoCEOBuy200,000$4.00$800,000.00View SEC Filing  
5/27/2014James A GeraghtyDirectorBuy10,000$2.65$26,500.00View SEC Filing  
12/6/2013James A GeraghtyDirectorBuy40,000$2.72$108,800.00View SEC Filing  
9/16/2013James A GeraghtyDirectorBuy60,000$1.90$114,000.00View SEC Filing  
8/19/2013James A GeraghtyDirectorBuy300,000$1.75$525,000.00View SEC Filing  
5/7/2013C Keith HartleyDirectorBuy90,000$0.49$44,100.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Idera Pharmaceuticals (NASDAQ:IDRA)
DateHeadline
News IconThe annual Dividend for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is $3 (NASDAQ:IDRA)
myhealthbowl.com - September 29 at 5:28 PM
News IconThe annual Dividend for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is $3 (NASDAQ:IDRA)
myhealthbowl.com - September 29 at 5:28 PM
News IconIdera Pharmaceuticals, Inc. (NASDAQ:IDRA) has the current quarter growth of -10% - Newburgh Press (NASDAQ:IDRA)
newburghpress.com - September 28 at 5:24 PM
News IconNews review of 2 biotech stocks: ImmunoGen, Inc. (NASDAQ:IMGN), Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - The Voice Registrar (NASDAQ:IDRA)
voiceregistrar.com - September 27 at 5:32 PM
News IconIdera Pharmaceuticals, Inc. (NASDAQ:IDRA) EPS Analysis - Newburgh Press (NASDAQ:IDRA)
newburghpress.com - September 27 at 5:32 PM
smarteranalyst.com logoCompany Update (NASDAQ:IDRA): Idera Pharmaceuticals Inc Reports Phase 1 Data Showing Encouraging Clinical ... - Smarter Analyst (NASDAQ:IDRA)
www.smarteranalyst.com - September 27 at 5:32 PM
smarteranalyst.com logoCompany Update (NASDAQ:IDRA): Idera Pharmaceuticals Inc Presents New Third Generation Antisense (3GA) Data at ... - Smarter Analyst (NASDAQ:IDRA)
www.smarteranalyst.com - September 27 at 5:32 PM
finance.yahoo.com logoIdera Pharmaceuticals Presents New Third Generation Antisense (3GA) Data at the 12th Annual Meeting of the Oligonucleotide Therapeutics Society (NASDAQ:IDRA)
finance.yahoo.com - September 27 at 10:07 AM
News IconIdera Pharmaceuticals Inc (NASDAQ:IDRA): Traders Insight’s Pick of The Day, Made 40% In Just One Week (NASDAQ:IDRA)
www.marketnewscall.com - September 26 at 5:39 PM
News IconIdera Pharmaceuticals Reports Promising Data from Ongoing Phase [..] (NASDAQ:IDRA)
www.pr-inside.com - September 26 at 10:11 AM
publicnow.com logoIdera Pharmaceuticals Reports Promising Data from Ongoing Phase 1 Dose Escalation in Clinical Trial of Intra-tumoral IMO-2125 in Combination with Ipilimumab in Patients with PD-1 Refractory Metasta... (NASDAQ:IDRA)
www.publicnow.com - September 26 at 10:11 AM
publicnow.com logoIdera Pharmaceuticals Reports Promising Data from Ongoing Phase 1 Dose Escalation in Clinical Trial of Intra-tumoral IMO-2125 in Combination with Ipilimumab in Patients with PD-1 Refractory Metastatic Melanoma (NASDAQ:IDRA)
www.publicnow.com - September 26 at 10:11 AM
News IconBiotech Stocks Worth a Closer Look: Threshold Pharmaceuticals (NASDAQ:THLD), Idera Pharmaceuticals (NASDAQ ... - The Voice Registrar (NASDAQ:IDRA)
voiceregistrar.com - September 25 at 4:58 PM
News IconFilipino leader curses out European Union over calls to halt drug killings (NASDAQ:IDRA)
avauncer.com - September 23 at 8:31 AM
News IconActive biotech company shares in the news: Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), Amicus Therapeutics, Inc ... - The Voice Registrar (NASDAQ:IDRA)
voiceregistrar.com - September 22 at 3:36 PM
News IconHot Biotech Stocks Recap: Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), Idera Pharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:IDRA)
voiceregistrar.com - September 22 at 3:36 PM
News IconBiotech news that matter for investors: CoLucid Pharmaceuticals (CLCD), Idera Pharmaceuticals (NASDAQ:IDRA) - The Voice Registrar (NASDAQ:IDRA)
voiceregistrar.com - September 21 at 3:48 PM
News IconPenny Stock Investors Take an Interest in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Duncan Research (NASDAQ:IDRA)
www.duncanindependent.com - September 21 at 3:48 PM
benzinga.com logoMid-Day Market Update: Tobira Therapeutics Jumps Following Allergan Buyout; HNI Shares Slide - Benzinga (NASDAQ:IDRA)
www.benzinga.com - September 21 at 3:48 PM
News IconPenny Stock Investors Keen on Shares of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Duncan Research (NASDAQ:IDRA)
www.duncanindependent.com - September 21 at 3:48 PM
News IconOverbuying Activity: Idera Pharmaceuticals Inc (NASDAQ:IDRA) - Post Registrar (NASDAQ:IDRA)
postregistrar.com - September 21 at 3:48 PM
nasdaq.com logoMid-Day Market Update: Tobira Therapeutics Jumps Following Allergan Buyout; HNI Shares Slide (NASDAQ:IDRA)
www.nasdaq.com - September 21 at 9:46 AM
News IconIdera Pharmaceuticals Inc (NASDAQ:IDRA): Our members Bought at $2.3, Up 20% In Just 24 Hours (NASDAQ:IDRA)
www.marketnewscall.com - September 21 at 9:45 AM
capitalcube.com logoETF’s with exposure to Idera Pharmaceuticals, Inc. : September 20, 2016 (NASDAQ:IDRA)
www.capitalcube.com - September 20 at 10:42 AM
News IconStock Update, a Closer Look at Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Duncan Research (NASDAQ:IDRA)
www.duncanindependent.com - September 15 at 5:55 PM
News IconKeen Investors Narrowing Their Focus on Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Duncan Research (NASDAQ:IDRA)
www.duncanindependent.com - September 15 at 8:45 AM
News IconGetting a Closer Look at Shares of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Duncan Research (NASDAQ:IDRA)
www.duncanindependent.com - September 12 at 5:25 PM
News IconStock Tracker: Earnings & Estimates for Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Frisco Fastball (NASDAQ:IDRA)
friscofastball.com - September 11 at 9:51 AM
News IconFocusing the Spotlight on Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Duncan Research (NASDAQ:IDRA)
www.duncanindependent.com - September 9 at 10:18 AM
capitalcube.com logoETF’s with exposure to Idera Pharmaceuticals, Inc. : September 8, 2016 (NASDAQ:IDRA)
www.capitalcube.com - September 8 at 5:28 PM
News IconA Second Look at Shares of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Duncan Research (NASDAQ:IDRA)
www.duncanindependent.com - September 2 at 5:32 PM
News IconHC Stocks News Ring - Sequenom, Inc. (NASDAQ:SQNM), Idera ... - share market updates (press release) (NASDAQ:IDRA)
sharemarketupdates.com - September 2 at 5:32 PM
smarteranalyst.com logoWedbush Positive on Idera Pharmaceuticals Inc (IDRA); Sings the Praises of 3GA Technology - Smarter Analyst (NASDAQ:IDRA)
www.smarteranalyst.com - August 26 at 5:25 PM
capitalcube.com logoETF’s with exposure to Idera Pharmaceuticals, Inc. : August 26, 2016 (NASDAQ:IDRA)
www.capitalcube.com - August 26 at 5:25 PM
News IconLooking Closer at Stocks of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Duncan Research (NASDAQ:IDRA)
www.duncanindependent.com - August 24 at 5:28 PM
finance.yahoo.com logo7:03 am Idera Pharma presents new pre-clinical data 'that demonstrates the novel gene-silencing mechanism of action of the third generation antisense technology platform' (NASDAQ:IDRA)
finance.yahoo.com - August 24 at 8:39 AM
publicnow.com logoIdera Pharmaceuticals Presents the Novel Mechanism of Action of its Third Generation Antisense Technology (NASDAQ:IDRA)
www.publicnow.com - August 24 at 8:39 AM
News IconSmall Cap Insight on Shares of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Duncan Research (NASDAQ:IDRA)
www.duncanindependent.com - August 20 at 5:25 PM
News IconCrowd Perspectives & Analyst Views on Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)? - Post News (NASDAQ:IDRA)
www.kentuckypostnews.com - August 20 at 9:46 AM
News IconEarnings in Perspective for Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Post News (NASDAQ:IDRA)
www.kentuckypostnews.com - August 19 at 5:32 PM
News IconPenny Stock Alert - Update & Review on This Stock: Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Duncan Research (NASDAQ:IDRA)
www.duncanindependent.com - August 19 at 5:32 PM
investornewswire.com logoWill Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Hit $6 Price Target? - Investor Newswire (NASDAQ:IDRA)
www.investornewswire.com - August 19 at 5:32 PM
kcregister.com logoMorning Alert: Idera Pharmaceuticals (NASDAQ:IDRA), Allot ... - KC Register (NASDAQ:IDRA)
www.kcregister.com - August 18 at 5:35 PM
News IconTaking A Closer Look at Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Duncan Research (NASDAQ:IDRA)
www.duncanindependent.com - August 18 at 8:35 AM
News IconSmall Cap Update on: Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Duncan Research (NASDAQ:IDRA)
www.duncanindependent.com - August 16 at 5:46 PM
News IconA Closer Look at Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Duncan Research (NASDAQ:IDRA)
www.duncanindependent.com - August 16 at 5:46 PM
finance.yahoo.com logoIdera to Present at the 2016 Wedbush PacGrow Healthcare Conference (NASDAQ:IDRA)
finance.yahoo.com - August 12 at 5:38 PM
capitalcube.com logoETF’s with exposure to Idera Pharmaceuticals, Inc. : August 12, 2016 (NASDAQ:IDRA)
www.capitalcube.com - August 12 at 5:38 PM
capitalcube.com logoIdera Pharmaceuticals, Inc. :IDRA-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016 (NASDAQ:IDRA)
www.capitalcube.com - August 11 at 5:49 PM
streetupdates.com logoAnalyst's Notable Buzzers: Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) , Emergent Biosolutions, Inc. (NYSE:EBS) - Street Updates (NASDAQ:IDRA)
www.streetupdates.com - August 10 at 8:25 AM

Social

Idera Pharmaceuticals (NASDAQ:IDRA) Chart for Saturday, October, 1, 2016


Last Updated on 10/1/2016 by MarketBeat.com Staff